Publications by authors named "R Dumaine"
Background: The appropriate duration of treatment with beta-blocker drugs after a myocardial infarction is unknown. Data are needed on the safety and efficacy of the interruption of long-term beta-blocker treatment to reduce side effects and improve quality of life in patients with a history of uncomplicated myocardial infarction.
Methods: In a multicenter, open label, randomized, noninferiority trial conducted at 49 sites in France, we randomly assigned patients with a history of myocardial infarction, in a 1:1 ratio, to interruption or continuation of beta-blocker treatment.
Article Synopsis
- The study aimed to assess the effectiveness of ticagrelor versus clopidogrel in preventing cardiovascular events among chronic coronary syndrome patients undergoing complex percutaneous coronary interventions (PCI).
- Among 1,866 patients in the trial, nearly half were identified as having complex PCI, which was associated with significantly higher rates of myocardial infarction and other complications.
- Despite the increased risk associated with complex PCI, ticagrelor did not demonstrate any advantage over clopidogrel in reducing these adverse events.
Article Synopsis
- The study aimed to investigate the effects of the timing of P2Y inhibitor administration on myocardial necrosis during elective percutaneous coronary intervention (PCI), utilizing data from the ALPHEUS trial.
- Results revealed that patients who received P2Y inhibitors closer to the PCI procedure had higher rates of myocardial necrosis compared to those who were given the medication earlier, with improved outcomes seen in groups that received longer loading times.
- While the study found a correlation between timing and myocardial injury, it noted that bleeding complications were minimal and did not vary significantly among the different timing groups, leaving long-term clinical effects unclear.
Background: The long-term use of β-blocker after myocardial infarction (MI) when global left ventricular ejection fraction (LVEF) is preserved has not been studied in the era of modern myocardial reperfusion and secondary prevention therapies. It is unknown whether β-blockers are useful in stable post-MI patients without reduced LVEF and without heart failure.
Methods: The Assessment of β-blocker interruption 1 Year after an uncomplicated myocardial infarction on Safety and Symptomatic cardiac events requiring hospitalization (ABYSS) Trial enrolled in 49 centers in France, 3,700 patients with a prior (>6 months) history of MI and a LVEF >40%, chronically treated with a β-blocker and without any major cardiovascular event (MACE) in the past 6 months.
Lamotrigine is widely prescribed to treat bipolar neurological disorder and epilepsy. It exerts its antiepileptic action by blocking voltage-gated sodium channels in neurons. Recently, the US Food and Drug Administration issued a warning on the use of Lamotrigine after observations of conduction anomalies and Brugada syndrome patterns on the electrocardiograms of epileptic patients treated with the drug.
View Article and Find Full Text PDF